IBBJ - Defiance Junior Biotech ETF
| Assets | $7.89M |
| NAV | $31.58 |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Beta (5Y) | 2.13 |
| Dividend (ttm) | $0.30 |
| Dividend Yield | 0.95% |
| Ex-Dividend Date | Dec 29, 2020 |
| 1-Year Return | - |
| Trading Day | April 21 |
| Last Price | $32.23 |
| Previous Close | $31.21 |
| Change ($) | 1.02 |
| Change (%) | 3.27% |
| Day's Open | 31.40 |
| Day's Range | 31.40 - 32.23 |
| Day's Volume | 2,910 |
| 52-Week Range | 22.85 - 41.45 |
Fund Description
The investment seeks to track the total return performance, before fees and expenses, of the NASDAQ Junior Biotechnology Index. The index is a rules-based index that consists of a portfolio of the stock of U.S.-listed small capitalization (junior) biotechnology companies (collectively, Junior Biotech Companies). The fund will generally use a replication strategy to achieve its investment objective, meaning it will generally invest in all of the component securities of the index in the same approximate proportions as in the index. The fund is non-diversified.
| Asset Class Equity | Inception Date Aug 3, 2020 |
| Exchange NASDAQ | Ticker Symbol IBBJ |
| Index Tracked Nasdaq Junior Biotechnology Index | |
Top 10 Holdings
18.52% of assets| Name | Symbol | Weight |
|---|---|---|
| BridgeBio Pharma | BBIO | 2.36% |
| Zai Lab | ZLAB | 2.27% |
| Fate Therapeutics | FATE | 2.00% |
| GW Pharmaceuticals | GWPH | 1.85% |
| Pacific Biosciences of California | PACB | 1.77% |
| Twist Bioscience | TWST | 1.75% |
| Medpace Holdings | MEDP | 1.68% |
| Vir Biotechnology | VIR | 1.64% |
| Halozyme Therapeutics | HALO | 1.61% |
| Allakos | ALLK | 1.58% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 24, 2021 | $0.00 | Mar 26, 2021 |
| Dec 29, 2020 | $0.30 | Dec 31, 2020 |
Small cap stocks are retreating. So are biotechnology names.
After a lull in mergers and acquisitions activity, Big Pharma could begin to use its cash stores to buy out smaller targets, potentially fueling the momentum in biotechnology-related exchange traded fun...
There are recipes for success for new exchange-traded funds. In an effort to attract assets and investors' attention, rookie ETFs can undercut established rivals on fees, offer exposure to a compelling ...
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is just a few months in, but it's already asserting itself in the biotechnology exchange traded funds arena, one teeming with competition. IBBJ tracks...
NEW YORK--(BUSINESS WIRE)---- $IBBJ #Biotech--About Defiance: Founded in 2018, Defiance ETFs is an exchange-traded funds (ETFs) sponsor and registered investment advisor, focused on thematic investing. ...
After a superb August, September looks gloomy for Wall Street. Still,
The S&P 500, the Dow Jones and the Nasdaq Composite have lost about 0.6%, 0.03% and 0.6%, respectively, past week.
Biotechnology mergers and acquisitions appear to be back in a big way with news that Gilead Sciences (NASDAQ: GILD) is acquiring Immunomedics (NASDAQ: IMMU) for $21 billion.
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is still in its infancy in the biotechnology ETFs arena, having debuted just last month, but a big opportunity comes with this rookie ETF. IBBJ tracks...
The Defiance Nasdaq Junior Biotechnology ETF (NYSE: IBBJ) is the newest addition to the biotechnology exchange traded funds fray, having debuted about a month ago.
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
ETF Trends CEO Tom Lydon discussed the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) on this week’s “ETF of the Week” podcast with Chuck Jaffe on the MoneyLife Show. IBBJ covers companies around the g...
The Defiance Nasdaq Junior Biotechnology ETF (IBBJ) is one of the newest exchange traded funds on the market and it could be one of the most appropriate for the current environment. IBBJ’s 176 member fi...
Extending what’s been a busy stretch of unique healthcare ETF launches, the Defiance Nasdaq Junior Biotechnology ETF (IBBJ) debuted on Tuesday, coming to market at a time when biotechnology ETFs, broadl...
With significant help from the fight against the coronavirus, biotechnology stock and exchange-traded funds are setting torrid paces this year.
New fund invests in small-cap biotechnology stocks.
Defiance ETFs debuted a new ETF today with targeted exposure to the junior disruptors in the biotech space.